Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07727148

FASC: Fish Allergy in Spanish Children - A Study of New Cases of Fish Allergy in Children and Adolescents

Fish allergy is one of the leading causes of food-induced allergic reactions in children, but the clinical presentation and patterns of sensitization vary considerably among patients and geographical regions. This prospective multicenter observational study aims to characterize children and adolescents with newly diagnosed IgE-mediated fish allergy in Spain.

Clinical information, diagnostic test results, and molecular sensitization profiles will be collected using standardized procedures across participating centers. Molecular allergy assessment will include component-resolved diagnostics to evaluate sensitization to major fish allergens and other relevant allergenic protein families. The study will also assess disease severity, quality of life, and regional differences in sensitization patterns.

The results are expected to improve the understanding of pediatric fish allergy in Spain and contribute to more accurate diagnosis, risk assessment, and personalized management of affected patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Observational

About this study

Fish allergy is a major cause of IgE-mediated food allergy in children and is associated with a wide spectrum of clinical manifestations, ranging from mild reactions to severe anaphylaxis. Current knowledge of pediatric fish allergy is limited by geographical differences in dietary habits, fish species consumed, and patterns of allergen sensitization. Although component-resolved diagnostics have improved the characterization of fish allergy, comprehensive multicenter studies in children remain scarce.

The FASC study is a prospective, multicenter, observational study conducted in Spain to characterize children and adolescents with newly diagnosed IgE-mediated fish allergy. Consecutive eligible patients will be recruited in participating pediatric allergy units using standardized diagnostic and data collection procedures. Clinical information, allergy history, skin testing, serum specific IgE measurements, and molecular sensitization profiles will be collected. When clinically indicated, oral food challenges will be performed according to international recommendations and routine clinical practice.

The study aims to describe clinical phenotypes, molecular sensitization patterns, disease severity, quality of life, and geographical variability across Spain. The findings are expected to improve the understanding of pediatric fish allergy, support the identification of clinically relevant sensitization profiles, and contribute to more accurate diagnosis and individualized patient management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children and adolescents aged 0 to 17 years (up to 18 years of age).
  • First clinical episode compatible with IgE-mediated fish allergy.
  • Evidence of allergic sensitization demonstrated by at least one of the following:
  • Positive skin prick test (wheal diameter ≥3 mm compared with the negative control); or
  • Serum specific IgE ≥0.35 kUA/L to at least one fish species or fish allergen component.
  • Written informed consent obtained from the parent(s) or legal guardian(s), and assent from participants aged 12 years or older, when applicable.

Exclusion criteria

  • Age ≥18 years.
  • Non-IgE-mediated fish allergy (e.g., fish-induced FPIES).
  • Severe dermographism, chronic urticaria, or severe atopic dermatitis preventing reliable interpretation of skin prick testing.
  • Inability to complete the diagnostic procedures required by the study.
  • Absence of informed consent or, when applicable, participant assent.

Treatment and study plan

Primary outcomes

  1. Prevalence of sensitization to clinically relevant fish allergen components.

    Time frame: Baseline (Day 1)

    Distribution of molecular sensitization profiles to clinically relevant fish allergen components and allergenic protein families in children and adolescents with newly diagnosed IgE-mediated fish allergy, as determined by component-resolved diagnostics performed at study enrollment.

Secondary outcomes

  1. Sensitization to individual fish allergen components

    Time frame: Baseline (Day 1)

    Frequency and distribution of sensitization to individual fish allergen components and allergenic protein families measured by component-resolved diagnostics.

  2. Specific IgE sensitization profile

    Time frame: Baseline (Day 1)

    Serum specific IgE sensitization to fish species and allergenic components determined using standardized laboratory methods.

  3. Oral food challenge outcome

    Time frame: During the diagnostic evaluation (up to 3 months after baseline (Day 1))

    Results of oral food challenges, including confirmation of clinical allergy and identification of tolerated fish species, when clinically indicated.

  4. Health-related quality of life

    Time frame: Baseline (Day 1) and at completion of the diagnostic evaluation (up to 3 months after baseline (Day 1))

    Health-related quality of life assessed using validated food allergy-specific quality-of-life questionnaires.

  5. Geographical variability in sensitization profiles

    Time frame: Through study completion, an average of 18 months

    Comparison of molecular sensitization profiles and clinical characteristics across participating regions in Spain.

Sponsors and collaborators

Lead sponsor

Carmelo Escudero

Other

Registry information

Official study title

IgE-Mediated Fish Allergy in Spanish Children and Adolescents: A Multicenter Prospective Study of New-Onset Cases and Sensitization Profiles.

Acronym: FASC

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.